Research Article

Efficacy and Safety of Indigo Naturalis in Combination with Narrow-Band Ultraviolet B for Treatment of Pityriasis Rosea: A Meta-Analysis

L. Wang,1 Y. N. Xue,1,2 Z. W. Li,1 W. Zhang,1 X. P. Ji,3 Z. Fan,4 and Y. J. Li1

1Department of Scientific Research, The First Affiliated Hospital, Xi’an Medical University, Xi’an, China
2Department of Pharmacy, The Second Hospital of Hanbin, Ankang, China
3Department of Traditional Chinese Medicine, The First Affiliated Hospital, Xi’an Medical University, Xi’an, China
4Department of Dermatology, The First Affiliated Hospital, Xi’an Medical University, Xi’an, China

Correspondence should be addressed to L. Wang; 394004312@qq.com and Y. J. Li; liyajun9@hotmail.com

Received 29 August 2017; Revised 22 November 2017; Accepted 3 December 2017; Published 27 March 2018

Academic Editor: Chang G. Son

Copyright © 2018 L. Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pityriasis rosea (PR), a skin rash, causes substantial discomfort in patients. There is a lack of effective therapies for PR. A combination of ultraviolet irradiation and indigo naturalis treatment has been shown to be a safe and effective regime for control of PR; however, the data have been largely inconsistent. This meta-analysis further evaluated the efficacy and safety of this combination in patients with PR. The PubMed, Embase, Cochrane Library, CNKI, VIP, and Wan Fang databases were searched for relevant RCTs of this combination therapy in patients with PR. A total of eight studies with a combined study population of 688 patients published between January 2006 and March 2016 were eligible for this meta-analysis. The RevMan 5.3 software was used for the meta-analysis. The regimen of compound indigo naturalis plus NB-UVB showed much better control of PR as compared to that achieved with use of compound indigo naturalis or NB-UVB alone in terms of cure rate or effective rate. However, no significant difference was observed between the two with respect to incidence of adverse effects. The analysis was affected by publication bias as revealed by funnel plot analysis. Further studies with large sample sizes are required to confirm our findings.

1. Introduction

Pityriasis rosea (PR) is a common skin disorder characterized by rash and substantial discomfort. Clinically, PR is an acute self-limiting inflammatory disease that accounts for 0.3%–3% of new patient consultations at dermatology clinics [1]. PR more commonly affects children and young adults; peak incidence is in the age group of 10–35 years. The disease is uncommon in patients younger than 10 years of age [2]. The disease typically resolves within one to three months; however, it significantly impacts the quality of life of the patients. The exact cause of PR is not clear; however, it may be related to viral infection, especially infection with human herpes viruses 6 and 7 [3, 4]. Antiviral therapy (such as acyclovir) has been shown to reduce the duration and severity of the disease [5–7]. The diagnosis of PR is usually based on clinical signs and symptoms. A set of validated diagnostic criteria for PR are available; these include essential clinical features of discrete circular or oval lesions, scaling on most lesions, or peripheral collarette scaling with central clearance in at least two lesions [8, 9]. There are several forms of PR including the relapsing form, the persistent form, and the pityriasis rosea-like eruptions [10–13]. Treatment of PR is usually symptomatic and there is no evidence to support the efficacy of specific therapies. However, previous studies have shown that ultraviolet irradiation and/or indigo naturalis are safe and effective treatment options for control of PR. Exposure to direct sunlight was shown to induce quick resolution of the lesions, which is the underlying rationale for the use of ultraviolet irradiation as a treatment modality [14].

Indigo naturalis (Qing Dai), extracted from the stems and leaves of Baphicacanthus cusia (Ness) Bremek, has been commonly used as a traditional Chinese remedy for various inflammatory disorders including dermatoses [15].
Oral administration of *indigo naturalis* has been used to treat psoriasis in China and its efficacy has been proved in several clinical studies [16]. Irradiation with narrow-band ultraviolet B (NB-UVB) at 311 nm wavelength was shown to alleviate erythema associated with lesions or rash [17], inhibiting keratinocyte proliferation. Oral compound indigo naturalis capsule alleviates “pathogenic heat” (a traditional Chinese medicine term, which could be referred to as antiviral effects) from the blood and ecchymosis [17]. Such an external treatment in combination with internal treatment could accrue full advantage of Chinese and Western medicine to effectively control PR and shorten the disease course. However, the efficacy of such combination treatment is still unclear or inconsistent. Approximately 50% of patients with PR experience moderate-to-severe itch and it is not known whether such treatment is effective and whether the combination could outweigh the risk of adverse effects. Thus, in this meta-analysis, we further evaluated the efficacy and safety of this combination in patients with PR.

### 2. Materials and Methods

#### 2.1. Data Sources and Search Strategy. **We** conducted a search for randomized controlled trials of compound indigo naturalis in combination with NB-UVB in patients with pityriasis rosea on PubMed, Embase, the Cochrane Library, the China National Knowledge Infrastructure (CNKI) database, and the Chinese Scientific Journals Full-Text Database (CQVIP). The reference period for the literature search was from January 2006 to March 2016. We utilized the search terms of compound indigo naturalis, narrow-band ultraviolet B, rose rosea, and randomized controlled trials with adjustments for different databases. The reference lists of eligible studies retrieved from the databases were manually searched to identify additional studies. During extraction of publications, we avoided subjective bias by omitting names of the authors, journals, year, and country.

#### 2.2. Inclusion and Exclusion Criteria. The abstracts of the retrieved studies were independently searched and reviewed by two investigators (W. Zhang and Z. W. Li) and the full texts of the selected studies were further evaluated for eligibility and inclusion in the meta-analysis. Any disagreements were resolved by consensus after consultation with a third reviewer (Z. Fan). A study was considered eligible if it met the following criteria: (1) patients with rose rosea diagnostic criteria; (2) patients did not receive corticosteroids, immunosuppressants, antihistamines, or other drugs in 2 weeks; and (3) patients without other diseases. The exclusion criteria were as follows: (1) patients allergic to UV irradiation; (2) pregnant and lactating women; (3) patients with severe heart, liver, kidney, gastrointestinal, and other diseases; and (4) rose rosea with infection.

#### 2.3. Data Extraction. According to Cochrane methodology, two investigators (Z. W. Li and Y. N. Xue) independently extracted data pertaining to study characteristics in a standardized spreadsheet and assessed the methodological quality of the included studies.

2.4. **Quality Assessment.** The quality of this meta-analysis was ensured by scores and all the included studies were categorized according to the Quality Assessment of Diagnostic Accuracy Studies [18], which includes 14 items to assess all included studies.

2.5. **Interventions and Outcome of Treatment.** The treatment group received oral compound indigo pills or capsules in combination with NB-UVB, while the control group received either oral compound indigo pills/capsules or NB-UVB treatment.

The cure rate, the effective rate, and the incidence rate of adverse reactions were assessed in each patient after treatment. Clinical efficacy was rated as follows: (1) cure: rash reduced by >90% and complete resolution of itching; (2) markedly effective: rash reduced by >60% and significant reduction in itching; (3) effective: rash reduced by >30% and reduction in itching; (4) ineffective: rash reduced by 30% or less and no relief of itching.

\[
\text{Recovery rate} = \left( \frac{\text{number of cases cured}}{\text{observed number of cases}} \right) \times 100; \\
\text{Efficiency rate} = \left( \frac{\text{number of cases cured} + \text{markedly case}}{\text{observed cases}} \right) \times 100.
\]

2.6. **Statistical Analysis.** RevMan 5.3 software [Review Manager version 5.3, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014] was used to analyze the data, that is, classification of data and calculation of risk ratios (RR) and 95% confidence intervals (95% CI). Heterogeneity across studies was assessed using the Cochrane $I^2$ statistics. $I^2 < 50\%$ was considered indicative of a lack of significant heterogeneity among the included studies and a fixed-effects model was used for analysis. $I^2 > 50\%$ was considered indicative of substantial heterogeneity and a random-effects model was used for analysis. In order to assess the influence of individual studies on the pooled analysis, a sensitivity analysis was performed by exclusion of individual studies, one at a time, to determine the stability of the meta-analysis. The analytic results were further shown using the forest plot, while a funnel plot was used to evaluate possible publication bias.

The Ethics Committee of the First Affiliated Hospital of Xian Medical University approved the study.

### 3. Results

#### 3.1. Data Retrieval. A total of 968 publications were retrieved on initial database search. The titles and abstracts were screened against the inclusion and exclusion criteria. Finally, we obtained eight randomized controlled trials with a combined study population of 688 subjects; among these, 333 subjects were in the treatment group and 355 subjects were in the control group [17, 19–25]. A schematic illustration of the literature search is shown as a flow chart in Figure 1. All eight
The basic characteristics of the included studies are listed in Table 1. The age of participants in the included studies ranged between 16 and 85 years. All eight studies specified the adverse reaction that mainly included erythema, thermalgia, itch, and diarrhea (Table 2). Five studies compared combined therapy with compound indigo naturalis, and four studies used NB-UVB as the control intervention. Treatment
<table>
<thead>
<tr>
<th>Author, year</th>
<th>cases</th>
<th>Combination</th>
<th>Single</th>
<th>Intervention and measures</th>
<th>Single</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhu et al., 2008 [17]</td>
<td>43</td>
<td>42</td>
<td>Compound indigo capsules p.o. 4 tablets t.i.d.; dexamethasone (DXM) cream ad us. ext.s.m.d</td>
<td></td>
<td>Compound indigo capsules p.o. 4 tablets t.i.d.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NB-UVB irradiation (311 nm): starting irradiation dose 0.39–0.50 J/cm², increased by 0.1 J/cm² every time q.o.d.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wa et al., 2010 [19]</td>
<td>33</td>
<td>32</td>
<td>Compound indigo capsules p.o. 4 tablets t.i.d.</td>
<td>NB-UVB irradiation: starting irradiation dose 0.5–0.7 MED increased by 0.1 J/cm² every time q.o.d.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liu et al., 2011 [20]</td>
<td>33</td>
<td>29/32</td>
<td>Compound indigo capsules p.o. 4 tablets t.i.d.</td>
<td>Control group 1: compound indigo capsules p.o. 4 tablets t.i.d.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NB-UVB irradiation (311–313 nm): starting irradiation dose 0.3–0.5 J/cm² increased by 10%–20% once q.o.d.</td>
<td>Control group 2: NB-UVB irradiation (311–313 nm): starting irradiation dose 0.3–0.5 J/cm² increased by 10%–20% once q.o.d.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sun et al., 2012 [21]</td>
<td>31</td>
<td>29</td>
<td>Compound indigo pill p.o. 2 g t.i.d.</td>
<td>Compound indigo pill p.o. 2 g t.i.d.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NB-UVB irradiation (311 nm): starting irradiation dose 0.35 J q.o.d. increased by 0.1 J once q.o.d.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhao et al., 2012 [22]</td>
<td>39</td>
<td>38</td>
<td>Compound indigo pill p.o. 2 g t.i.d.</td>
<td>NB-UVB irradiation q.o.d., Calamine lotion ad us.ext</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NB-UVB irradiation q.o.d., Calamine lotion ad us.ext</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhao and Sun, 2013 [23]</td>
<td>60</td>
<td>60</td>
<td>Compound indigo capsules p.o. 4 tablets t.i.d.</td>
<td>Compound indigo capsules p.o. 4 tablets t.i.d.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NB-UVB irradiation exposure done 0.2 J/cm² t.i.w.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xu et al., 2014 [24]</td>
<td>40</td>
<td>42</td>
<td>Compound indigo capsules p.o. 4 tablets t.i.d.</td>
<td>NB-UVB irradiation (311 nm): starting irradiation dose 0.4–0.6 J/cm² b.i.w.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Li, 2014 [25]</td>
<td>54</td>
<td>51</td>
<td>Compound indigo pills p.o. 6 g t.i.d.</td>
<td>Compound indigo pills p.o. 6 g t.i.d.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NB-UVB irradiation (311 nm): starting irradiation dose 0.4–0.5 J/cm² q.o.d. increased Clobetasol propionate ointment</td>
<td>Clobetasol propionate ointment</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Primary outcome: ○ the cure rate; ◯ the effective rate; and □ the incidence rate of adverse reaction.
Table 2: Adverse reactions in each study.

<table>
<thead>
<tr>
<th>Included studies</th>
<th>Test group</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adverse reaction</td>
<td>Erythema</td>
</tr>
<tr>
<td>Zhu et al. 2008 [17]</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Wa et al. 2010 [19]</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>Liu et al. 2011 [20]</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Liu et al. 2011 [20]</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Sun et al. 2012 [21]</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Zhao et al. 2012 [22]</td>
<td>3</td>
<td>NA</td>
</tr>
<tr>
<td>Zhao and Sun 2013 [23]</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Xu et al. 2014 [24]</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Li 2014 [25]</td>
<td>3</td>
<td>3</td>
</tr>
</tbody>
</table>
3.2. Data Analysis

3.2.1. Compound Indigo Naturalis in Combination with NB-UVB versus Compound Indigo Naturalis Alone. Five trials reported the cure rate and the effective rate of compound indigo naturalis in combination with NB-UVB and compound indigo naturalis alone as the control intervention. As shown in Figure 2, heterogeneity analysis indicated no significant heterogeneity between these two treatment groups. Therefore, the fixed-effects model was used for data analysis. The data showed that the cure rate and the effective rate of compound indigo naturalis in combination with NB-UVB were higher than that of compound indigo naturalis alone (OR = 2.45, 95% CI: 1.63–3.68, and P < 0.0001 and OR = 4.52, 95% CI: 2.60–7.87, and P < 0.0001).

The incidence rates of adverse reactions were reported for four trials (compound indigo naturalis plus NB-UVB versus compound indigo naturalis alone). As shown in Figure 2, no significant heterogeneity was observed between these two groups (I² = 0%; P = 0.53); therefore, the fixed-effects model was used for data analysis. No significant difference with respect to the incidence of adverse reactions was observed between the experimental and control groups (OR = 2.45, 95% CI: 0.87–6.90, and P = 0.09).

3.2.2. Compound Indigo Naturalis in Combination with NB-UVB versus NB-UVB Alone. Five trials reported the cure rate, the effective rate, and the incidence rate of adverse reaction after treatment of pityriasis rosea with compound...
indigo naturalis plus NB-UVB and NB-UVB alone. As shown in Figure 3, heterogeneity analysis indicated no significant heterogeneity between these two groups and the fixed-effects model was used for data analysis. We found that the cure rate and the effective rate of the combination therapy was much higher than that of NB-UVB alone (the between-group difference was markedly significant (OR = 3.34, 95% CI: 2.04–5.48, and \( P < 0.00001 \) and OR = 5.04, 95% CI: 2.65–9.57, and \( P < 0.00001 \), resp.). No significant between-group difference was observed with respect to the incidence rate of adverse reactions (OR = 1.12, 95% CI: 0.57–2.23, and \( P = 0.74 \)).

3.2.3. Assessment of Publication Bias. Next, we assessed the publication bias using Deeks’ test and the funnel plot shows the standard deviation of the effect size as the vertical coordinate and the numerical value as the horizontal coordinate by the effect of each research OR (Figure 4). The funnel plot showed an asymmetrical distribution of the samples which suggests that some of the test methodologies may have been of low quality and that the results may have been influenced by publication bias.

4. Discussion

Pityriasis rosea is a commonly encountered inflammatory skin disease in clinical settings. The skin rash typically appears on the trunk and proximal extremities and commonly occurs in the Spring and Autumn seasons. Although the disease is self-limiting [1], the disease course typically lasts
Moreover, NB-UVB has strong penetrability and does not cause skin burn or induce an erythematous reaction. Moreover, it does not overlap the DNA absorption peak and is not liable to cause mutation of genomic DNA in the skin cells [17]. NB-UVB treatment considerably reduces the severity of pityriasis rosea and hastens recovery. However, NB-UVB monotherapy for pityriasis rosea does have some limitations; for example, prolonged use of ultraviolet light can cause progressive damage to human skin, such as induction of genomic DNA mutations, damage to skin cells, collagen, and destruction of vitamins A and C in the skin. Thus, combination therapies reduce such side effects of NB-UVB. The present meta-analysis further indicates the superiority of combination regime of compound indigo naturalis plus NB-UVB over monotherapy for control of PR. The side effects of such regime were similar to those of monotherapies. In China, such a regime is called the combination of traditional Chinese medicine with modern Western medicine to achieve maximal effects with a concomitant reduction in side effects of single drug treatment. This synergistic effect may be attributable to improved local blood circulation because of natural medical herbs, which decreases or eliminates the side effects of local treatment, like NB-UVB.

However, our current study does have some limitations. For example, the number of studies and the sample size used in this analysis were relatively small. Moreover, the included studies did show some variability with respect to data analyses. Our results may also have been affected by publication bias. Thus, further validation study with a large cohort and independent patients is needed to confirm our findings. Future studies should investigate the efficacy of this regime with respect to control of erythema, itching, and time required for relief of itch.

5. Conclusion

Results from this study demonstrate that combination therapy with compound indigo naturalis plus NB-UVB is superior to monotherapy for control of pityriasis rosea. The side effects of such combination were similar to those of single treatment. Further clinical studies are required to confirm our findings.

Conflicts of Interest

The authors declare that they have no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

L. Wang and Y. N. Xue contributed equally to this work.

Acknowledgments

This study was supported in part by grants from Social Development, Science and Technology Research Projects of Shaanxi Province, China (no. 2015SF080), The Scientific Research Program of Shaanxi Provincial Education Department, China (no. 14JK628), and The Medical Project of
Bureau of Science and Technology of Xi’an City, China (no. SFLI418(5)).

References
